Aytu Biopharma (AYTU) director receives 10,000-share restricted stock grant

Rhea-AI Filing Summary

LIU VIVIAN H reported acquisition or exercise transactions in this Form 4 filing.

Aytu Biopharma director Vivian H. Liu received a grant of 10,000 shares of restricted common stock on July 28, 2026. The restricted stock vests on July 28, 2027. Following this grant, Liu directly holds 29,825 shares of Aytu Biopharma common stock.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider LIU VIVIAN H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 29,825 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest on July 28, 2027.

Key Figures

Restricted stock granted: 10,000 shares Holdings after grant: 29,825 shares Transaction price: $0.00 per share +1 more

4 metrics

Restricted stock granted 10,000 shares Grant of restricted common stock on July 28, 2026

Holdings after grant 29,825 shares Total common stock held directly following the transaction

Transaction price $0.00 per share Reported transaction price for the restricted stock grant

Vesting date July 28, 2027 Scheduled vesting date of the granted restricted stock

Key Terms

restricted stock, vesting, Grant, award, or other acquisition

3 terms

restricted stock financial

"Grant of restricted stock, which vest on July 28, 2027."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vesting financial

"Grant of restricted stock, which vest on July 28, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction code description "Grant, award, or other acquisition""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:32 PM Accepted by SEC EDGAR 07/30/2026 - 04:32 PM Learn about SEC filing dates

FAQ

What insider transaction did AYTU director Vivian H. Liu report?

Director Vivian H. Liu reported receiving a grant of 10,000 shares of Aytu Biopharma common stock. The award is in the form of restricted stock that will vest after one year, adding to her existing equity position in the company.

How many AYTU shares were granted to Vivian H. Liu in this Form 4?

Vivian H. Liu was granted 10,000 shares of Aytu Biopharma common stock. These shares are classified as restricted stock, meaning they are subject to vesting conditions before becoming fully transferable to her.

When do Vivian H. Liu’s restricted AYTU shares vest?

The 10,000 shares of restricted Aytu Biopharma stock granted to Vivian H. Liu vest on July 28, 2027. Until that vesting date, the shares remain subject to the restrictions described as part of the restricted stock award.

What is Vivian H. Liu’s total AYTU shareholding after this grant?

Following the restricted stock grant, Vivian H. Liu directly holds 29,825 shares of Aytu Biopharma common stock. This figure reflects her total direct ownership immediately after the reported July 28, 2026 transaction.

Was the AYTU insider transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the reported restricted stock grant is not disclosed as being made pursuant to a Rule 10b5-1 trading plan adopted under SEC rules.

What price was reported for Vivian H. Liu’s AYTU restricted stock grant?

The restricted stock grant to Vivian H. Liu shows a reported transaction price of $0.00 per share. This reflects that the award was an equity grant rather than a market purchase involving cash consideration from the director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIU VIVIAN H

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		10,000(1)	A	$0	29,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest on July 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for Vivian H. Liu	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)